Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar 14:5:99.
doi: 10.3389/fmicb.2014.00099. eCollection 2014.

The impact of antifungals on toll-like receptors

Mircea R Mihu  1 , Rodney Pattabhi  1 , Joshua D Nosanchuk  2
Affiliations
Review

The impact of antifungals on toll-like receptors

Mircea R Mihu et al. Front Microbiol. .

Abstract

Fungi are increasingly recognized as major pathogens in immunocompromised individuals. With the increase in the number of fungal infections each year and the development of resistance to current therapy, new approaches to treatment including stimulation of the immune response in addition to concurrent pharmacotherapy is ongoing. The most common invasive fungal infections are caused by Candida spp., Aspergillus spp., and Cryptococcus spp. Amphotericin B (AmB) has remained the cornerstone of therapy against many fulminant fungal infections but its use is limited by its multitude of side effects. Echinocandins are a newer class of antifungal drugs with activity against Candida spp. and Aspergillus spp. and constitutes an alternative to AmB due to superior patient tolerability and fewer side effects. Due to their oral delivery, azoles continue to be heavily used for simple and complex diseases, such as fluconazole for candidal vaginitis and voriconazole for aspergillosis. The objective of this paper is to present current knowledge regarding the multiple interactions between the broad spectrum antifungals and the innate immune response, primarily focusing on the toll-like receptors.

Keywords: amphotericin B; antifungals; caspofungin; echinocandins; toll-like receptors; voriconazole.

PubMed Disclaimer

References

    1. Adjou K. T., Deslys J. P., Demaimay R., Dormont D. (1997). Probing the dynamics of prion diseases with amphotericin B. Trends Microbiol. 5 27–3110.1016/S0966-842X(97)81771-4 - DOI - PubMed
    1. Aerts A. M., Francois I. E., Cammue B. P., Thevissen K. (2008). The mode of antifungal action of plant, insect and human defensins. Cell Mol. Life Sci. 65 2069–207910.1007/s00018-008-8035-0 - DOI - PMC - PubMed
    1. Arning M., Kliche K. O., Heer-Sonderhoff A. H., Wehmeier A. (1995). Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38 459–465 10.1111/j.1439-0507.1995.tb00020.x - DOI - PubMed
    1. Bellocchio S., Gaziano R., Bozza S., Rossi G., Montagnoli C., Perruccio K., et al. (2005). Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 55 214–22210.1093/jac/dkh542 - DOI - PubMed
    1. Blanco J. L., Garcia M. E. (2008). Immune response to fungal infections. Vet. Immunol. Immunopathol. 125 47–7010.1016/j.vetimm.2008.04.020 - DOI - PubMed

LinkOut - more resources